F/M Emerald Life Sciences Innovation ETF (LFSC)

Assets	$116.79M
Expense Ratio	0.54%
PE Ratio	39.47
Forward PE	24.73
Shares Out	2.78M
Dividend	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a

Volume	1,368
Open	41.42
Previous Close	40.75
Day's Range	41.40 - 41.53
52-Week Low	30.45
52-Week High	48.78
Beta	0.94
Holdings	40
Inception Date	Oct 31, 2024

About LFSC

Fund Home Page

The F/M Emerald Life Sciences Innovation ETF (LFSC) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed ETF that targets US health care and biotechnology companies identified to have promising life sciences opportunities. LFSC was launched on Oct 31, 2024 and is issued by F/m Investments.

• Asset Class: Equity
• Category: Health
• Region: North America
• Stock Exchange: Nasdaq
• Ticker Symbol: LFSC
• ETF Provider: F/m Investments

Top 10 Holdings

53.65% of assets

Name	Symbol	Weight
Corcept Therapeutics Incorporated	CORT	7.81%
LivaNova PLC	LIVN	7.08%
Travere Therapeutics, Inc.	TVTX	6.39%
Cogent Biosciences, Inc.	COGT	5.82%
Guardant Health, Inc.	GH	5.38%
Spyre Therapeutics, Inc.	SYRE	5.06%
BillionToOne, Inc.	BLLN	4.49%
Replimune Group, Inc.	REPL	4.35%
Veradermics, Incorporated	MANE	3.79%
TransMedics Group, Inc.	TMDX	3.49%

Performance

LFSC had a total return of 38.49% in the past year, including dividends. Since the fund's inception, the average annual return has been 29.56%.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP. Several fund data points are also provided by Finnhub.

Last checked:

Oct 16, 2026

Data Sources Report a data error